Clinical Trials Logo

Clinical Trial Summary

The RAATE proposal is designed to determine the effects of physical activity on risk factors for Alzheimer's Disease in older African American adults. The study will compare a physical activity program to an active control group. There are three main objectives of the protocol: 1) to determine if a physical activity intervention tailored to older African American adults is effective in modifying cognitive function associated with Alzheimer's Disease, 2) to determine if a physical activity intervention tailored to older African American adults is effective in modifying brain function and structure associated with Alzheimer's Disease, and 3) to determine if a physical activity promotion intervention tailored to African American adults is effective at enhancing physiological parameters. The primary endpoints for the study are episodic memory and executive functioning. The secondary outcomes include anthropometry, blood pressure, brain activation, cerebral blood flow, volume of whole brain and white matter hyperintensities, cardiorespiratory fitness, objectively measured physical activity, circulating hormones, and telomere length.


Clinical Trial Description

Alzheimer's disease is steadily increasing in prevalence, with a devastating public health impact. The prevalence of Alzheimer's Disease is higher in African Americans compared to white Americans, thereby constituting a health disparity. Interventions that prevent Alzheimer's disease or change the course of cognitive decline associated with Alzheimer's disease are needed. Most older adults do not achieve recommended levels of physical activity, and this includes African Americans. Regular physical activity has proven to be a safe and effective means to enhance cognitive function in older adults ranging from cognitively healthy to mildly cognitively impaired. Therefore, our study is focused on physical activity promotion, a potent approach to modifying multiple neurobiological pathways implicated in Alzheimer's Disease. We evaluate exercise benefits among elderly African Americans, who are understudied and in whom the natural course of neurodegeneration, exercise effects on neuroprotection and neurodegeneration, and resulting clinical phenotypes may differ. A large body of existing data suggests that exercise improves cardiovascular and cerebrovascular functioning, and thus has the potential to enhance perivascular clearance of amyloid and reduce chronic brain tissue ischemia, among other beneficial effects. At the same time, chronic exercise has been shown to decrease central levels of inflammatory markers and increase central levels of neurotrophic factors, which in turn promote protection against Alzheimer's Disease neurodegeneration pathways via a variety of mechanisms. While physical activity interventions have been shown to have positive effects on these factors and on resultant cognitive functioning in older adults, nearly all interventions have had a negligible representation of African Americans. Prior data suggests that African Americans enter their elderly years against a backdrop of different lifespan exposures to a variety of factors relevant to neuroprotection and neurodegeneration, including cardiovascular risk, exercise, diet, and education. In addition, prior data suggests that the key genetic risk factor for Alzheimer's Disease (APOE) may have differing consequences for Alzheimer's Disease risk among African Americans, and other genetic differences have the potential to influence the brain benefits of physical activity in this community. We will utilize a randomized clinical trial to addresses these questions. Participants will be randomized into a physical activity promotion intervention or a healthy aging information group for 52 weeks. All participants will be of normal cognitive function. We will assess cognitive function, brain structure and function, circulating hormones, objectively measured physical activity, cardiorespiratory fitness, and telomere length. Our study will take the first step toward understanding whether the hypothesized benefits of exercise for the brain carry over to elderly African Americans. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03890861
Study type Interventional
Source Pennington Biomedical Research Center
Contact Melissa Harris, PhD
Phone 225763091
Email Melissa.Harris@pbrc.edu
Status Recruiting
Phase N/A
Start date August 9, 2019
Completion date November 30, 2026

See also
  Status Clinical Trial Phase
Not yet recruiting NCT00154635 - Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer’s Disease Phase 2
Completed NCT00208819 - A Comparison of Two Standard Therapies in the Management of Dementia With Agitation Phase 4
Completed NCT00997425 - Home Evaluation of Exit Barriers in Wandering N/A
Terminated NCT02322021 - Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease Phase 2
Completed NCT03119259 - Technology Intervention to Support Caregiving for Alzheimer's Disease (I-CARE) N/A
Completed NCT00099242 - Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease Phase 3
Completed NCT03721705 - Renew NCP-5 for the Treatment of Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild Dementia of the Alzheimer's Type Phase 3
Not yet recruiting NCT05113732 - Association of Cognition With Functional Mobility in People With Alzheimer's Disease
Active, not recruiting NCT03661034 - Study of Tolerability, Safety and Efficacy of Sensory Stimulation at Multiple Dose Levels to Improve Brain Function (Etude Study) N/A
Completed NCT03160027 - Photobiomodulation for Improving Brain Function in Dementia (PBM Dementia) N/A
Completed NCT03475316 - Movement Intervention for Memory Enhancement N/A
Completed NCT02727699 - A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu) Phase 2
Completed NCT00259454 - Project COPE:Managing Dementia at Home Phase 3
Completed NCT00505167 - Memantine Versus Donepezil in Early Stages of Alzheimer's Disease Phase 4
Completed NCT03246269 - Normative Values for the German Version of the Montreal Cognitive Assessment (MoCA)
Completed NCT03991195 - Intervention of Intestinal Microorganism in Mild Cognitive Impairment N/A
Completed NCT00515333 - TRx0014 in Patients With Mild or Moderate Alzheimer's Disease Phase 2
Completed NCT01438060 - Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type Phase 3
Completed NCT03622814 - Partners at Meals - Respite Care and Home (PAM) N/A
Recruiting NCT03672266 - Studies of Brain and Body Interaction